论文信息 - Ursodeoxycholic acid in primary sclerosing cholangitis

Ursodeoxycholic acid in primary sclerosing cholangitis

REFERENCES 1. Tinsley A, Machlin EA, Korcenik JR, et al. Validation of the Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F) in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 1328–36. 2. Fayers PM, Machin D. Quality of Life: The Assessment, Analysis and Interpretation of Patient‐Reported Outcomes. Chichester: John Wiley & Sons Ltd, 2007. 3. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147–53. 4. Jelsness‐Jørgensen LP, Bernklev T, Henriksen M, et al. Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls. Inflamm Bowel Dis 2011; 17: 1564–72. 5. Jelsness‐Jørgensen LP, Bernklev T, Henriksen M, et al. Chronic fatigue is associated with impaired health‐related quality of life in inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 106–14.

A. Burroughs | C. Triantos | N. Koukias | V. Nikolopoulou

[1] J. Korzenik,et al. Validation of the Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F) in patients with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.

[2] K. Lindor,et al. High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis , 2011, Alimentary pharmacology & therapeutics.

[3] A. Burroughs,et al. Meta‐analysis: ursodeoxycholic acid for primary sclerosing cholangitis , 2011, Alimentary pharmacology & therapeutics.

[4] T. Bernklev,et al. Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls , 2011, Inflammatory bowel diseases.

[5] T. Bernklev,et al. Chronic fatigue is associated with impaired health‐related quality of life in inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.

[6] K. Boberg,et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. , 2005, Gastroenterology.

[7] W. Kremers,et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. , 2001, Gastroenterology.

[8] S. Wessely,et al. Development of a fatigue scale. , 1993, Journal of psychosomatic research.

[9] P. Fayers,et al. Quality of Life: The assessment, analysis and interpretation of patient-reported outcomes , 2007 .